logo-loader
RNS
viewSummit Therapeutics PLC

Summit Therapeutics to Present at the 2020 BIO CEO & Investor Conference

Summit Therapeutics plc 
(‘Summit’ or the ‘Company’)

Summit Therapeutics to Present at the 2020 BIO CEO & Investor Conference

Oxford, UK, and Cambridge, MA, US, 4 February 2020Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces that Mr Glyn Edwards, Chief Executive Officer, will present at the 2020 BIO CEO & Investor Conference on 10 February 2020 at 2:15pm EST in New York City.

A live webcast of the presentation will be available in the Investors section of the Company's website, www.summitplc.com. A replay of the webcast will be available from the same location soon after the live presentation.

About Summit Therapeutics
Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for infections caused by C. difficile, Enterobacteriaceae and N. gonorrhoeae and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit www.summitplc.com and follow us on Twitter @summitplc.

Contacts

Summit    
Glyn Edwards / Richard Pye (UK office) Tel: 44 (0)1235 443 951
Michelle Avery (US office)   +1 617 225 4455
     
Cairn Financial Advisers LLP (Nominated Adviser) Tel: +44 (0)20 7213 0880
Liam Murray / Tony Rawlinson / Ludovico Lazzaretti    
     
N+1 Singer (Joint Broker) Tel: +44 (0)20 7496 3000
Aubrey Powell / George Tzimas, Corporate Finance
Tom Salvesen, Corporate Broking
   
     
Bryan Garnier & Co Limited (Joint Broker) Tel: +44 (0)20 7332 2500
Phil Walker / Dominic Wilson

 
   
MSL Group (US) Tel: +1 781 684 6552
Erin Anthoine   [email protected]
     
Consilium Strategic Communications (UK) Tel: +44 (0)20 3709 5700
Mary-Jane Elliott / Sue Stuart / Sukaina Virji   [email protected]
Lindsey Neville    

-END-

Quick facts: Summit Therapeutics PLC

Price: -

Market: AIM
Market Cap: -
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Summit Therapeutics pleased with new BARDA partnership investment

Summit Therapeutics PLC (NASDAQ:SMMT) (LON:SUMM) Investor Relations Senior Director Michelle Avery sat down with Proactive's Christine Corrado at BIO CEO in New York. The company recently announced The Biomedical Advanced Research and Development Authority (BARDA) is investing a further $8.8mln...

on 02/10/2020